MedTrace Logo

Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

NCT01021943 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-07-24

No results posted yet for this study

Summary

The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors

Conditions

  • Kidney Transplant

Interventions

DRUG

spironolactone

Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months

DRUG

Placebo

Half of the subjects will be assigned to receive placebo for 6 months

Sponsors & Collaborators

  • Instituto Nacional de Cardiologia Ignacio Chavez

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01021943 on ClinicalTrials.gov